Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer

• Published in: Anticancer research Vol. 44; no. 6; p. 2725
• Main Authors: Ano, Satoshi, Kikuchi, Norihiro, Okauchi, Shinichiro, Numata, Takeshi, Nakamura, Ryota, Shiozawa, Toshihiro, Watanabe, Hiroko, Tamura, Tomohiro, Miyazaki, Kunihiko, Hayashi, Shigen, Yamashita, Takaaki, Kurishima, Koichi, Inagaki, Masaharu, Kaburagi, Takayuki, Endo, Takeo, Satoh, Hiroaki, Hizawa, Nobuyuki
• Format: Journal Article
• Language: English
• Published: Greece 01-06-2024
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; Progression-Free Survival; Small Cell Lung Carcinoma - drug therapy; Small Cell Lung Carcinoma - mortality; Small Cell Lung Carcinoma - pathology; overall survival; chemotherapy; progression-free survival; immune-related adverse events; Atezolizumab
• ISSN: 1791-7530
• DOI: 10.21873/anticanres.17080

Atezolizumab, an anti-PD-L1 antibody, has been increasingly administered in combination with chemotherapy to patients with small cell lung cancer (SCLC). This study aimed to determine how patients with extensive disease (ED) -SCLC responded to atezolizumab with chemotherapy and found factors affecting long-term response and survival.
This study focused on patients with SCLC who were treated with a combination of atezolizumab and chemotherapy in Japan between 2019 and 2023. Patient information and tumor response were analyzed, along with adverse events. We compared data and estimated survival probabilities.
In our clinical trial, 95 patients with SCLC who received this treatment had a median progression-free survival of 6.0 months and a median overall survival of 15.0 months. Immune-related adverse events were observed in 13.7% of the patients, with grade 3 or higher in 5.3%. The efficacy and immune-related adverse events associated with this treatment regimen were comparable to those reported in previous clinical trials. Progression-free survival >2 years was observed in a small number of patients (5.3%).
Our research will offer important insights for the future care of patients with extensive-stage SCLC by utilizing atezolizumab in combination with chemotherapy. Accumulation and confirmation of clinical practice results will have important implications for the future implementation of this therapy.